Should I buy Teva Pharmaceuticals stock in 2025?

What is Teva Pharmaceuticals?

How much is the Teva Pharmaceuticals stock?

The price of Teva Pharmaceuticals stock is declining this week. As of now, TEVA shares are trading at $17.53, marking a 3.42% drop over the past 24 hours and a 3.36% decrease across the week. The company's market capitalisation stands at $20.35 billion, with a 3-month average daily volume of 12.3 million shares. The price/earnings (P/E) ratio is currently not applicable due to recent losses, and no dividend yield is offered. TEVA’s beta is 0.63, suggesting relatively low volatility compared to the wider market—an aspect that may appeal to cautious investors monitoring stability within the pharmaceutical sector.

Our full analysis on Teva Pharmaceuticals stock

Having closely analysed Teva Pharmaceuticals' (NYSE: TEVA) latest quarterly and annual results, as well as its share price evolution over the last three years, we have leveraged a suite of data-driven approaches encompassing financial ratios, proprietary technical signals, real-time market dynamics, and detailed peer benchmarking. Synthesising these insights through our advanced algorithms, we arrive at a crucial consideration for 2025: why might Teva Pharmaceuticals stock once again become a strategic entry point into the ever-evolving global healthcare and biotechnology sector?

Recent Performance and Market Context

Teva has displayed resilient stock behaviour despite episodic intraday volatility, currently trading at $17.53 (as of May 30th, 2025). Over the past 52 weeks, TEVA shares have oscillated between $12.47 and $22.80, revealing sizeable upside potential from the current price, especially given the consensus analyst target of $23.12. After a modest 6.57% gain over the past year and a 4.47% rise in the last six months, the stock nevertheless finds itself down 20.46% year-to-date—an apparent lag that, on closer analysis, highlights a possible opportunity amid sector rotation and investor repositioning.

Crucially, Teva reported its ninth consecutive quarter of revenue growth through Q1 2025. The health of its innovative product portfolio, especially the outperformance of treatments like AUSTEDO ($1.6bn revenue in 2024, ahead of expectations) and UZEDY ($117m in 2024 versus a $100m target), has provided a robust fundamental platform. Meanwhile, the pharmaceutical sector continues to enjoy a favourable macro backdrop, with global demand for generic and specialty medications on the rise amid regulatory tailwinds in the US and EU. For IE investors, exposure to global players like Teva offers appealing diversification in both currency and market dynamics.

Technical Analysis

Teva’s technical landscape is currently neutral with an emerging bullish tilt. The 14-day Relative Strength Index (RSI) stands at 49.05—firmly neutral but close to levels where upward momentum often builds. The MACD (+0.09) flashes a buy signal, indicating a favourable shift in price momentum, while the Stochastic (9,6) at 17.37 places the stock in oversold territory—suggesting that downside risk is becoming increasingly limited.

• 5-day MA: $17.49 (buy signal)
• 50-day MA: $17.20 (buy signal)
• 100-day MA: $17.22 (buy signal)
• 200-day MA: $16.28 (buy signal)

The most prominent technical support is identified at $17.34 (near today's low), while resistance stands at $18.28 (today's high). This compact trading range highlights a consolidation phase, typically the precursor to renewed strength if catalysts unfold.

Overall, technical indicators reinforce the notion that Teva may be entering a new bullish phase, and that the share is well-supported for accumulation near recent lows.

Fundamental Analysis

Teva’s transformation over the past two years is underpinned by operational excellence and strategic vision. Annual revenue for 2024 reached $16.54bn (+6% in local currencies), and adjusted EBITDA climbed to $4.78bn. Notably, Q4 free cash flow was $790m, and full-year free cash flow hit $2.07bn, indicating strong underlying performance.

While trailing earnings (TTM EPS: -$1.15) remain negative due to legacy challenges, the company’s non-GAAP EPS for 2024 stood at an impressive $2.49—comfortably beating expectations and demonstrating the underlying health of core operations. The lack of a current dividend redistributes resources towards R&D and debt reduction, both prudent at this phase of Teva's evolution.

Teva’s structural strengths should not be underestimated:

• Innovation pipeline: 18 biosimilar assets in development.
• Market share: Leadership in generics across the US and Europe.
• Brand: Recognised as a trusted supplier to healthcare systems globally.
• Management: Strategic “Pivot to Growth” is reaffirmed each quarter, under CEO Richard Francis.

Volume and Liquidity

Teva is consistently one of the most actively traded pharmaceutical stocks on the NYSE, with a 3-month average daily trading volume of 12.3 million shares. This high liquidity provides a dynamic environment for both retail and institutional investors, translating to orderly price discovery and tight bid-ask spreads. The outstanding float (1.15bn shares) supports a market that can absorb significant inflows without distorting valuation, and also allows for relatively efficient portfolio rebalancing—an appealing characteristic for active investors in IE seeking overseas equities.

Catalysts and Positive Outlook

• Product Innovation: AUSTEDO and UZEDY are rapidly becoming blockbuster anchors.
• Pipeline Expansion: The expected launch of SELARSDI and positive FDA ‘Fast Track’ designation for TEV-53408 (celiac disease) are set to drive news flow.
• Clinical Milestones: Duvakitug (anti-TL1A) is moving into pivotal Phase 3 trials in 2025 after promising Phase 2B results.
• Biosimilars: With 18 assets progressing, Teva is well-placed to address the vast “patent cliff” opportunity as leading biologics go off-patent.
• Operational Momentum: Nine consecutive quarters of growth, ongoing deleveraging (total debt falling from elevated levels), and improved free cash generation.

The sector context also remains constructive. Global health expenditure continues to trend higher, and innovation in specialty generics and biosimilars remains a coveted growth avenue—particularly as payors and health services worldwide seek cost containment and improved outcomes.

Investment Strategies

Teva’s risk-reward balance appears increasingly favourable across investment horizons:

• Short-Term Entry
• Recent pullback to strong technical support at $17.34
• Oversold short-term indicators and impending catalyst events (product launches, regulatory decisions)
• Attractive swing trade potential as price compresses towards the lower end of the 2025 analyst target range
• Medium-Term Positioning
• Building a position ahead of major pipeline announcements (SELARSDI launch, Duvakitug Phase 3)
• Outlook for sustained EBITDA and free cash margin expansion
• Potential for positive earnings surprises as analyst estimates remain conservative
• Re-rating opportunity as sector sentiment rotates back into undervalued growth names
• Long-Term Strategy
• Exposure to secular innovation in global healthcare, with a deeply diversified product base and geographic reach (57 markets, ~37,000 employees)
• Leadership in generics and biosimilars, well-suited for multiyear growth as demographic and regulatory trends remain supportive
• Consistent deleveraging and operational discipline increase resilience and optionality for value creation

For investors seeking a portfolio anchor in global pharma, accumulation near the current technical floor could be prudent ahead of a possible multi-quarter recovery.

Is it the Right Time to Buy Teva Pharmaceuticals?

Synthesising the analysis, Teva Pharmaceuticals emerges as a company decisively transitioning from a legacy turnaround story to a pioneering global player with clear leadership in generics, specialty pharmaceuticals, and biosimilars. The recent string of outperformance, robust pipeline maturation, and strategic focus under CEO Richard Francis are fundamentally altering the risk/reward proposition.

• Multiple consecutive quarters of earnings outperformance and revenue growth
• Significant new product catalysts (AUSTEDO, UZEDY, SELARSDI, Duvakitug)
• Expanding biosimilars and innovation pipelines
• Strong liquidity, institutional ownership, and high trading volume
• Valuation that remains attractive relative to peers despite visible growth momentum

While investors should remain mindful of moderate risks such as the company’s leverage (albeit on a downward trajectory) and its geopolitical exposure, these appear well-priced into the market. Analyst consensus is converging towards a more constructive stance, and recent upgrades reflect an emerging appreciation for Teva’s compelling growth profile.

In conclusion, Teva Pharmaceuticals seems to represent an excellent opportunity for investors looking to gain exposure to the convergence of healthcare innovation and global market diversification. With fundamentals and technicals aligning favourably and a pipeline brimming with near-term and long-term catalysts, Teva may be entering a fresh bullish phase that merits careful consideration as part of a diversified portfolio. For those seeking quality at a cyclical low, the current environment provides a strategic window to participate in the company’s renewed ascent.

How to buy Teva Pharmaceuticals stock in Ireland?

Buying shares in Teva Pharmaceuticals (ticker: TEVA), a leading global pharmaceutical company, is now simple and secure for Irish investors thanks to regulated online brokers. You can invest by purchasing actual Teva shares (“spot buying”) or trading using Contracts for Difference (CFDs), each offering distinct benefits. Spot buying means you own the shares directly, suitable for long-term investors, while CFDs allow you to speculate on price movements with leverage—ideal for short-term strategies. Below, we detail these two main approaches, with a useful broker comparison further down this page.

Spot Buying

A cash or spot purchase of Teva Pharmaceuticals stock means you buy real TEVA shares on the New York Stock Exchange, becoming a shareholder with voting rights and potential for capital gains. Most Irish-friendly brokers charge a fixed commission per order—typically between $4 and $10 (or the euro equivalent), often around $5 for modest amounts.

Example

Suppose the Teva share price is $17.53. With a $1,000 investment and a $5 brokerage fee, you could buy approximately 56 shares ($1,000 - $5 = $995; $995 ÷ $17.53 ≈ 56 shares).

Gain scenario: If the share price rises by 10%, your holding is now worth about $1,100 (56 × [$17.53 × 1.10]). Result: +$100 gross gain, or +10% on your initial investment (excluding taxes and currency conversion if applicable).

Trading via CFD

CFD trading allows you to speculate on the price changes of Teva Pharmaceuticals without owning the actual shares. CFDs typically require a lower capital outlay and offer leverage (often up to 5:1 for EU investors), amplifying both potential gains and risks. The main fees are the spread (the difference between buy and sell price) and overnight financing if you hold positions beyond a single day.

Example

You open a CFD position on Teva shares with $1,000 using 5x leverage, giving you market exposure of $5,000.

Gain scenario: If Teva’s price rises by 8%, your leveraged position grows by 8% × 5 = 40%. On your $1,000 initial margin, that’s a $400 gross gain (before subtracting spread and any overnight financing fees).

Final Advice

Before investing, carefully compare brokers’ fees, account types, and regulatory safeguards—these can impact both your costs and security as an Irish investor. Your chosen method will depend on your goals: spot buying suits long-term wealth building, while CFDs are aimed at experienced investors seeking short-term opportunities. A detailed broker comparison is available further down this page to help you make an informed, confident choice.

Our 7 tips for buying Teva Pharmaceuticals stock

The latest news about Teva Pharmaceuticals

Teva Pharmaceuticals has maintained nine consecutive quarters of revenue growth, affirming the effectiveness of its "Pivot to Growth" strategy. This sustainable expansion, confirmed most recently in Q1 2025, has been underpinned by robust sales across both generics and specialty products, demonstrating resilience in global markets, including Ireland, where Teva maintains a direct presence supporting local healthcare infrastructure. The company’s ongoing transformation under CEO Richard Francis, especially through operational refinements and a sharpened commercial focus, provides a constructive backdrop for continued recovery and positions Teva as a stable pharmaceutical partner for Irish healthcare providers.

Key innovative products, particularly AUSTEDO and UZEDY, have recorded performance exceeding expectations, driving strong momentum across developed markets. In 2024, AUSTEDO generated over $1.6 billion in revenues and UZEDY achieved $117 million—both surpassing internal targets—with AUSTEDO’s success reinforcing Teva’s footing in neurology and movement disorders, areas of significant therapeutic need in Ireland. This success story is relevant for the Irish market, as AUSTEDO is increasingly prescribed for Huntington’s disease and tardive dyskinesia, with reimbursement pathways aligning to HSE guidelines. The company’s strong specialty portfolio, coupled with a growing biosimilar pipeline, enhances access to affordable medicines for regional healthcare systems.

Teva has recently achieved a crucial regulatory milestone, securing US FDA Fast Track designation for TEV-53408 in celiac disease, alongside positive Phase 2B results for Duvakitug (Anti-TL1A). This advancement is significant for Irish analysts, as Ireland faces one of Europe’s highest celiac prevalence rates, and regulatory accelerations in the US are likely to influence the speed of European Medicines Agency (EMA) reviews. Such progress underscores Teva’s rising innovation credentials, potentially leading to earlier Irish availability of targeted therapies for autoimmune and gastrointestinal diseases, supporting unmet medical needs and broadening Teva’s relevance within the Irish market landscape.

Teva’s technical indicators, as of late May 2025, show a broadly neutral stance with positive bias, supported by buy signals on several key moving averages. Specifically, the 5-day, 50-day, 100-day, and 200-day moving averages all point to buy conditions, while the MACD remains positive. The company’s Relative Strength Index (RSI) hovers near 49, suggesting neither overbought nor oversold status, with the stochastic oscillator in the oversold zone. These signals, together with a consensus analyst target price of approximately $23.12 (+30% upside from current levels), provide a constructive technical and sentiment framework relevant for Irish institutional investors seeking entry points or portfolio allocation adjustments.

Teva continues to deepen its engagement with the Irish market through substantial generic and biosimilar product distribution, supporting the HSE’s cost-containment priorities and patient access objectives. Operating in Ireland via integrated supply chains and direct sales channels, Teva secures its position as one of the primary contributors to national medicine savings, with a particular emphasis on chronic disease therapies. Expansion in biosimilars—now 18 assets in the pipeline—aligns with ongoing shifts in Irish health policy toward sustainable access and budget predictability, bolstering Teva’s strategic presence and dimming long-term competitive risks.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.